Sales & Marketing News | pharmaphorum

News

close up of a prescription bottle with white tables falling out on top of a group of hundred dollar bills

Endo files for bankruptcy as it agrees opioid settlement

Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that

News

First Zantac cancer case dropped before trial, without settl...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma compa

News

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medic

News

Roche eyes April FDA verdict on Polivy as first-line lymphom...

The FDA has started a review of Roche's Polivy for people with previously untreated diffuse large B-cell lymphoma (DLBCL), as the drugmaker tries to move the drug further up the treatment p

News

FDA grants swift review to Lynparza in first-line prostate c...

AstraZeneca and Merck & Co's PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marke

News

UK first to approve Moderna's Omicron booster jab

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

Endo files for bankruptcy as it agrees opioid settlement

First Zantac cancer case dropped before trial, without settl...

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

Roche eyes April FDA verdict on Polivy as first-line lymphom...

FDA grants swift review to Lynparza in first-line prostate c...

UK first to approve Moderna's Omicron booster jab

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks